AKYA
insider transactionsAkoya Biosciences, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·J
Director
$0
35.6K sh
-
Other·J
Director
$0
30.5K sh
-
Other·J
Director
$0
56.3K sh
-
Other·J
Director
$0
45.0K sh
-
Other·J
Director
$0
50.0K sh
-
Other·J
Director
—
28.5K sh
-
Other·J
Director
$0
50.0K sh
-
Other·J
Director
$0
56.3K sh
-
Other·J
Director
$0
30.5K sh
-
Other·J
Director
$0
16.9K sh
-
Other·J
Director
—
984.5K sh
-
Other·J
Director
$0
16.9K sh
-
Other·J
Director
$0
50.0K sh
-
Other·J
Director
$0
30.5K sh
-
Other·J
Director
$0
56.3K sh
-
Other·J
Chief Business Officer
$0
62.6K sh
-
Other·J
Chief Business Officer
$0
45.0K sh
-
Other·J
Chief Business Officer
$0
45.0K sh
-
Other·J
Chief Business Officer
$0
70.0K sh
-
Other·J
Chief Business Officer
—
62.6K sh
-
Other·F
Chief Business Officer
—
42.1K sh
Own -13%
-
Other·J
Chief Business Officer
—
130.6K sh
-
Other·J
Chief Business Officer
—
151.9K sh
-
Other·J
Director
$0
50.0K sh
-
Other·J
Director
$0
16.9K sh
-
Other·J
Director
$0
56.3K sh
-
Other·J
Director
$0
30.5K sh
-
Other·J
Director
—
234.6K sh
-
Other·J
Director
—
1.7M sh
-
Other·J
Director
—
15.9M sh
-
Other·J
Director
$0
16.9K sh
-
Other·J
Director
$0
50.0K sh
-
Other·J
Director
$0
30.5K sh
-
Other·J
Director
$0
56.3K sh
-
Other·J
Chief Legal Officer
$0
70.0K sh
-
Other·J
Chief Legal Officer
$0
75.0K sh
-
Other·J
Chief Legal Officer
—
16.8K sh
-
Other·J
Chief Legal Officer
—
162.5K sh
-
Other·J
Director
$0
30.5K sh
-
Other·J
Director
$0
56.3K sh
-
Other·J
Director
$0
50.0K sh
-
Other·J
Director
$0
39.0K sh
-
Other·J
Director
—
20.0K sh
-
Other·J
CFO
$0
160.0K sh
-
Other·J
CFO
$0
70.0K sh
-
Other·J
CFO
—
193.8K sh
-
Other·J
CFO
—
20.0K sh
-
Other·J
CFO
—
54.5K sh
-
Other·J
Chief Clinical Officer
$0
150.0K sh
-
Other·J
Chief Clinical Officer
$0
25.0K sh
-
Other·J
Chief Clinical Officer
$0
15.0K sh
-
Other·J
Chief Clinical Officer
$0
50.0K sh
-
Other·J
Chief Clinical Officer
—
9.5K sh
-
Other·J
Chief Clinical Officer
—
196.2K sh
-
Other·J
McKelligon Brian KEY
President and CEO
$0
175.0K sh
-
Other·J
McKelligon Brian KEY
President and CEO
$0
160.0K sh
-
Other·J
McKelligon Brian KEY
President and CEO
$0
160.0K sh
-
Other·J
McKelligon Brian KEY
President and CEO
$0
241.6K sh
-
Other·J
McKelligon Brian KEY
President and CEO
$0
393.3K sh
-
Other·J
McKelligon Brian KEY
President and CEO
$0
331.1K sh
-
Other·J
McKelligon Brian KEY
President and CEO
—
947.7K sh
-
Other·F
McKelligon Brian KEY
President and CEO
—
196.9K sh
Own -17%
-
Other·J
McKelligon Brian KEY
President and CEO
—
393.3K sh
-
Other·J
McKelligon Brian KEY
President and CEO
—
331.1K sh
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 8, 2025 | Mendel Scott | Other J | 35.6K | $0 |
| Jul 8, 2025 | Mendel Scott | Other J | 30.5K | $0 |
| Jul 8, 2025 | Mendel Scott | Other J | 56.3K | $0 |
| Jul 8, 2025 | Mendel Scott | Other J | 45.0K | $0 |
| Jul 8, 2025 | Mendel Scott | Other J | 50.0K | $0 |
| Jul 8, 2025 | Mendel Scott | Other J | 28.5K | — |
| Jul 8, 2025 | Winkler Matthew | Other J | 50.0K | $0 |
| Jul 8, 2025 | Winkler Matthew | Other J | 56.3K | $0 |
| Jul 8, 2025 | Winkler Matthew | Other J | 30.5K | $0 |
| Jul 8, 2025 | Winkler Matthew | Other J | 16.9K | $0 |
| Jul 8, 2025 | Winkler Matthew | Other J | 984.5K | — |
| Jul 8, 2025 | SHEPLER ROBERT G | Other J | 16.9K | $0 |
| Jul 8, 2025 | SHEPLER ROBERT G | Other J | 50.0K | $0 |
| Jul 8, 2025 | SHEPLER ROBERT G | Other J | 30.5K | $0 |
| Jul 8, 2025 | SHEPLER ROBERT G | Other J | 56.3K | $0 |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 62.6K | $0 |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 45.0K | $0 |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 45.0K | $0 |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 70.0K | $0 |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 62.6K | — |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other F | 42.1K | — |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 130.6K | — |
| Jul 8, 2025 | Ramachandran Niro Ph.D | Other J | 151.9K | — |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 50.0K | $0 |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 16.9K | $0 |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 56.3K | $0 |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 30.5K | $0 |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 234.6K | — |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 1.7M | — |
| Jul 8, 2025 | Raffin Thomas A. | Other J | 15.9M | — |
| Jul 8, 2025 | SCHNETTLER THOMAS P | Other J | 16.9K | $0 |
| Jul 8, 2025 | SCHNETTLER THOMAS P | Other J | 50.0K | $0 |
| Jul 8, 2025 | SCHNETTLER THOMAS P | Other J | 30.5K | $0 |
| Jul 8, 2025 | SCHNETTLER THOMAS P | Other J | 56.3K | $0 |
| Jul 8, 2025 | Kamocsay Jennifer | Other J | 70.0K | $0 |
| Jul 8, 2025 | Kamocsay Jennifer | Other J | 75.0K | $0 |
| Jul 8, 2025 | Kamocsay Jennifer | Other J | 16.8K | — |
| Jul 8, 2025 | Kamocsay Jennifer | Other J | 162.5K | — |
| Jul 8, 2025 | LAI GOLDMAN MYLA | Other J | 30.5K | $0 |
| Jul 8, 2025 | LAI GOLDMAN MYLA | Other J | 56.3K | $0 |
| Jul 8, 2025 | LAI GOLDMAN MYLA | Other J | 50.0K | $0 |
| Jul 8, 2025 | LAI GOLDMAN MYLA | Other J | 39.0K | $0 |
| Jul 8, 2025 | LAI GOLDMAN MYLA | Other J | 20.0K | — |
| Jul 8, 2025 | Ek John Frederick KEY | Other J | 160.0K | $0 |
| Jul 8, 2025 | Ek John Frederick KEY | Other J | 70.0K | $0 |
| Jul 8, 2025 | Ek John Frederick KEY | Other J | 193.8K | — |
| Jul 8, 2025 | Ek John Frederick KEY | Other J | 20.0K | — |
| Jul 8, 2025 | Ek John Frederick KEY | Other J | 54.5K | — |
| Jul 8, 2025 | BAMFORD PASCAL | Other J | 150.0K | $0 |
| Jul 8, 2025 | BAMFORD PASCAL | Other J | 25.0K | $0 |
| Jul 8, 2025 | BAMFORD PASCAL | Other J | 15.0K | $0 |
| Jul 8, 2025 | BAMFORD PASCAL | Other J | 50.0K | $0 |
| Jul 8, 2025 | BAMFORD PASCAL | Other J | 9.5K | — |
| Jul 8, 2025 | BAMFORD PASCAL | Other J | 196.2K | — |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 175.0K | $0 |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 160.0K | $0 |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 160.0K | $0 |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 241.6K | $0 |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 393.3K | $0 |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 331.1K | $0 |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 947.7K | — |
| Jul 8, 2025 | McKelligon Brian KEY | Other F | 196.9K | — |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 393.3K | — |
| Jul 8, 2025 | McKelligon Brian KEY | Other J | 331.1K | — |
About AKYA insider trading
This page tracks insider transactions for Akoya Biosciences, Inc. (AKYA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.